ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)PRNewsWire • 02/13/23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022PRNewsWire • 02/07/23
ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology ConferencePRNewsWire • 02/02/23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022PRNewsWire • 12/13/22
ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate CancerSeeking Alpha • 11/16/22
J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatmentMarket Watch • 10/31/22
ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR SymposiumPRNewsWire • 10/26/22
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific RetreatPRNewsWire • 10/26/22
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022PRNewsWire • 08/04/22
ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical DevelopmentPRNewsWire • 06/27/22
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022PRNewsWire • 05/10/22
ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor ConferencePRNewsWire • 04/26/22
ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain DegradersPRNewsWire • 04/08/22